About Dizal Company

The company is an innovative biomedical enterprise focusing on the research, development and commercialization of innovative therapies in the field of malignant tumors and immune diseases. The company adheres to the innovative R&D concept, with the goal of launching the world's first-in-class drugs (First-in-Class) and treatments with breakthrough potential, with the aim of filling the world's unmet clinical needs. Based on the industry-leading translational science and new drug molecular design and screening technology platform, the company has established six globally competitive product pipelines. Two leading products are in critical global clinical trials, and one of them has been approved for marketing. The company focuses on research, development and commercialization of innovative therapies in the field of malignant tumors and immune diseases. Main products: Sewazel, Goliximitinib, DZD8586, DZD6008. The company was recognized by the Wuxi Municipal Bureau of Industry and Information Technology as “2022 Wuxi Specialized, Special and New Small and Medium Enterprises”; selected as “2022 China Pharmaceutical Emerging Innovation Force” published by China Pharmaceutical Industry Information Center; won the “2022 Changchun Award Innovative Pharmaceutical Enterprise of the Year” by Interface News; won the “2022 China Listed Company Reputation List - Biomedical's Most Growing Listed Company” hosted by the Shanghai Biomedical Science and Technology Development Center and relevant organizations; selected as the “2022 Top 20 Most Influential Small Molecule Innovative Drug Companies” by the Shanghai Biomedical Technology Development Center and relevant organizations; in HR Media It was awarded honorary titles such as the “2022 Greater China Outstanding Employer Award” in the Greater China Human Resources Management Excellence Awards organized by the company HRoot.